Atormac
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 8553  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
    Next article
    Previous article
    Table of Contents

 Resource Links
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1798    
    Printed69    
    Emailed2    
    PDF Downloaded0    
    Comments [Add]    
    Cited by others 2    

Recommend this journal

 

 
Year : 1995  |  Volume : 43  |  Issue : 1  |  Page : 20--25

Intravenous with intrathecal interferon in subacute sclerosing panencephalitis.


Department of Neurology, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore - 560029

Correspondence Address:
KPS Nair
Department of Neurology, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore - 560029

Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 29542469

Rights and PermissionsRights and Permissions

Recent literature from different countries has revealed variable results of interferon treatment in subacute sclerosing panencephalitis (SSPE). Twelve patients with SSPE were treated at NIMHANS by concurrent use of intravenous and intrathecal interferon ALFA-2a, manufactured by recombinant DNA technology. The diagnosis of SSPE was based on clinical profile, EEG, CT and presence of antibody radio-immunoassay measles IgG antibodies in CSF. The total dose of interferon by intrathecal as well as intravenous route varied from 15 million to 60 million units. Clinical improvement as demonstrated by a decrease in scores on Neurological disability index occurred in three. Two of them relapsed five months after stopping the therapy but one patient maintained improvement two years after stopping treatment. There was no significant change in six patients. There were 3 deaths. One of them was autopsied. A decrease in titres of antimeasles antibody in CSF was noted in two patients who showed clinical improvement but in others there was no consistent correlation. No significant changes occurred in EEG during the treatment period. No serious side effect of interferon were encountered. Two patients had iatrogenic meningitis which could be treated successfully. Use of intravenous combined with intrathecal interferon is not promising in SSPE.






[PDF Not available]*


        
Print this article     Email this article

Online since 20th March '04
Published by Wolters Kluwer - Medknow